FDA Bans Compounded Versions of Ozempic and Zepbound
21 Mar 2025
The U.S. Food and Drug Administration (FDA) has ordered compounding pharmacies to cease manufacturing less expensive versions of popular weight-loss drugs like Ozempic and Zepbound. This move follows federal officials' determination that there is no longer a shortage of glucagon-like peptide-1 (GLP-1) drugs. The ban affects medications containing active ingredients...
Read More
